WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

REVIEW ON SUPERNUCLEAR PALSY DISORDER

Patil Anagha Prashant*, Patil Varsha B., Chaudhari Mayur A. and
Dr. Deshmukh Tushar A.

ABSTRACT

In recent years, anunusual syndrome of supranuclear palsy disorder, milddementia was described. The substrates of the new clinicopathologic entity of Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome. Tau-immunoreactive tufted astrocytes are the pathognomonic histological feature. PSP-tau is comprised predominantly of 4-repeat tau. High frequency of concomitant pathologies such as Alzheimer disease and argyrophilic grains in PSP may partly contribute to the clinical heterogeneity. It produces an akinetic-rigid form of parkinsonism characterized by early falls and abnormalities of extraocular movements. We also discuss useful imaging tools and review various management strategies. Clumps of tau are also characteristic of other neurodegenerative disorders, such as Alzheimer's disease. Rarely, progressive supranuclear palsy occurs within a family. Mean age of onset is approximately 63 years, and mean survival from symptom onset is 9 years. Women are less affected of PSP as compare to Men. It frequently much more found in men. Progressive Supranuclear Palsy (PSP) is an akinetic- rigid form of Parkinson Syndrome. We reviewed medical records of 16 patients with PSP identified. Neuroimaging in patients with PSP by computed tomography (CT) and MRI have shown atrophy and signal increase in the midbrain. The only proven risk factor for supranuclear palsy is age. Conventional structural brain MRI can helpon the differentiationbetween PSP and PD, and other atypical parkinsonian subtypes. A genetic variation in or near the tau gene on chromosome 17 appears to be associated with an increased risk of developing PSP. The Risk factor are only proven by age for PSP.

Keywords: Supranuclear Palsy Disorder, Alzheimer disease, Parkinson Syndrome, MRI, Age, Risk factor, SPECT imaging.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More